Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 1997

View Archived Issues

New compounds for heparin reversal disclosed by University of Michigan

Merck & Co. discloses novel antifungal agents

Thomae reports agents for hypercholesterolemia

More oxazolidinone antimicrobial agents under study at P&U

Neurogen reports CRF ligands for stress-related disorders

Chiroscience reports new peptidyl compounds for treating degenerative diseases

Nitric oxide synthase inhibitors reported by Searle

Company Profile: NeoTherapeutics, Inc.

cGMP PDE inhibitors from Taisho

Kao discloses cell adhesion inhibitors

Thomas Jefferson University claims new apoptotic cysteine protease

Genetics Institute reports new bone morphogenic protein

Amgen discloses novel eck receptor ligands

New Canadian generic joint venture

Carrington Laboratories enters Middle East and African markets

HemoCleanse licenses bioartificial liver technology from Monsanto

Canadian launch for antiobesity drug

Ion exercises option to license sickle cell anemia Rx

Cell Genesys and Somatix to merge

Subcutaneous BDNF not effective in ALS

Avid licenses protease inhibitor from DuPont Merck

Approval for Neoprobe's first product

Gliatech licenses ADCON products in Japan

Annual review of activities at Collagen Corp.

FDA to review AmBisome NDA

Company Profile: Houghten Pharmaceuticals

Second IND submitted for new ADHD therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...